·Î±×ÀÎ Àüü´º½º¿ÀÇǴϾðEnglishÆÊ ¾ÆÄ«µ¥¹ÌÆʽºÅ¸Å¬·´TVÆʵµ¶ó¸®Äí¸£Æ®DPºÎµ¿»êÀλ絿Á¤Event & Çмú¼¼¹Ì³ªµ¶ÀÚÁ¦º¸
°Ë»ö ä¿ëÁ¤º¸ º¹ÁöºÎ "Æó¾Ï¾à ·ÎºñÅ¥¾Æ, ÃÖ´ëÇÑ »¡¸® ±Þ¿© È®´ë" ±â»çÀÔ·Â : 24.10.16 17:12:03 0 °¡ ÇÃÄ£Ãß°¡ ÇöÀç Á¦¾à»ç¿Í Çù»ó Áß¡¦È¯ÀÚ ºÎ´ã ´úµµ·Ï ³ë·Â [µ¥Àϸ®ÆÊ=ÀÌŹ¼ø ±âÀÚ] º¹ÁöºÎ°¡ ALK ¾ç¼º ºñ¼Ò¼¼Æ÷Æó¾ÏÄ¡·áÁ¦ '·ÎºñÅ¥¾Æ(·Ñ¶óƼ´Õ)'ÀÇ 1Â÷ Ä¡·á ±Þ¿© È®´ë¿¡ ´ëÇØ ÃÖ´ëÇÑ »¡¸® ³ë·ÂÇÏ°Ú´Ù°í ¹àÇû´Ù. 16ÀÏ ¿¸° ±¹È¸ º¸°Çº¹ÁöÀ§¿øȸ ±¹Á¤°¨»ç¿¡¼ ÇÑÁö¾Æ ±¹¹ÎÀÇÈû ÀÇ¿øÀº ÇÑ ³²¼ºÀÇ »ç¿¬À» ¼Ò°³ÇÏ¸é¼ ·ÎºñÅ¥¾ÆÀÇ ±Þ¿©È®´ë ³»¿ëÀ» ¹°¾ú´Ù. ÇÑ ÀÇ¿ø¿¡ µû¸£¸é ÀÌ ³²¼ºÀº ALK ¾ç¼º ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ °É¸° ¾Æ³»¸¦ »ì¸®±â À§ÇØ ºñ±Þ¿©·Î ·ÎºñÅ¥¾Æ¸¦ ÇÑ´Þ 500¸¸¿ø µé¾î »ç¿ëÇÏ°í ÀÖ´Ù. ÇÏÁö¸¸ Á¡Á¡ ¾à°ªÀÌ ºÎ´ãÀÌ µÇ´Â »óȲ. ·ÎºñÅ¥¾Æ´Â ±Þ¿© ÀûÁ¤¼º ½É»ç¸¦ ³¡³»°í ¾à°¡Çù»ó±îÁö °¬Áö¸¸, ÇÕÀÇ°¡ ºÒ¹ßµÈ »óȲÀÌ´Ù. ÇÑ ÀÇ¿ø ÁúÀÇ¿¡ ÀÌÁß±Ô º¹ÁöºÎ °Ç°º¸ÇèÁ¤Ã¥±¹ÀåÀº "·ÎºñÅ¥¾Æ´Â ÇöÀç 1Â÷ Ä¡·á È®´ë ÀÛ¾÷À» ÇÏ°í ÀÖ´Ù"¸ç "Á¦¾à»ç¿Í Çù»óÇÏ°í ÀÖ´Ù"°í ¸»Çß´Ù. ±×·¯¸é¼ "ÃÖ´ëÇÑ »¡¸® Çù»óÇؼ ȯÀڵ鿡°Ô ÇýÅÃÀÌ µ¹¾Æ°¥ ¼ö ÀÖµµ·Ï µ½°Ú´Ù"°í µ¡ºÙ¿´´Ù. X AD ¼º£ÀÌ Âü¿© GO À̺¥Æ®Âü¿© ¡æ ÀÌŹ¼ø ±âÀÚ(hooggasi2@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç (Sr.) Local Research Specialist ¹Ù·Î°¡±â ÀÓ»óÆÀ PM °æ·Â(2³â ÀÌ»ó) ä¿ë ¹Ù·Î°¡±â ÀÓ»óÆÀ¿ø(Á¤±ÔÁ÷), RA/QAÆÀ¿ø,PVÆÀ¿ø(°è¾àÁ÷) ä¿ë ¹Ù·Î°¡±â Ç°Áú±×·ìÀå(ÀÌ»ç±Þ), °ü¸®¾à»ç ¸ðÁý ¹Ù·Î°¡±â [À¯¸í¿Ü±¹°èÁ¦¾à»ç] ½ÅÀÔ¾à»ç & °æ·Â MSL µî ´Ù¼ö ¹Ù·Î°¡±â Senior Regulatory Science Specialist(1Yr) ¹Ù·Î°¡±â Á¶¾ÆÁ¦¾à Ç°Áú°ü¸®¾à»ç °æ·Â ä¿ë ¹Ù·Î°¡±â °³¹ß±âȹÆÀ BD °æ·Â(7³â ÀÌ»ó)ä¿ë ¹Ù·Î°¡±â ¢ß¼¿Æ®¸®¿ÂÁ¦¾à ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë ¹Ù·Î°¡±â Æĸ¶¿¡¼¾½Ã¾ÆÄÚ¸®¾Æ MSL ½Å±Ô ä¿ë ¹Ù·Î°¡±â ÇØÅÂhtb ÀÍ»ê°øÀå °ü¸®¾à»ç ä¿ë ¹Ù·Î°¡±â (ÀüºÏ(ÀüÁÖ °ÅÁÖ)) ¿µ¾÷ºÎ ½ÅÀÔ/°æ·ÂÁ÷(ÁÖÀÓ~´ë¸®±Þ) ¸ðÁý ¹Ù·Î°¡±â Medical Representative (Á¾º´ ¿µ¾÷ - °è¾àÁ÷) ¹Ù·Î°¡±â Junior Marketing Manager ä¿ë ¹Ù·Î°¡±â PMS Lead (Fixed-term) ¹Ù·Î°¡±â Medical Science Liaison (Oncology) / Head of Market Access & External Affairs / MR(¿µ¾÷ºÎ) ä¿ë ¹Ù·Î°¡±â Çѱ¹¿¡ÀÚÀÌ Medical Scientific Affair ä¿ë(À°¾ÆÈÞÁ÷´ëü_±â°£Á¦) ¹Ù·Î°¡±â Medical Representative (Ŭ¸®´Ð ¿µ¾÷ - °è¾àÁ÷) ¹Ù·Î°¡±â Çѱ¹¿¡ÀÚÀÌ Sr. MSL Associate ä¿ë(Á¤±ÔÁ÷) ¹Ù·Î°¡±â Á¦¾à¾à»çä¿ë ¹Ù·Î°¡±â ¸¶ÄÉÆà ¾à»ç, Àü¹®¿¬±¸¿ä¿ø ¸ðÁý ¹Ù·Î°¡±â QC, QA, Medical Affairs, MR(º´¿ø¿µ¾÷) ä¿ë ¹Ù·Î°¡±â Sr. Regulatory Affairs Specialist (18 months contract) ¹Ù·Î°¡±â ´õÇö´ë ¼¿ï ÇÍŸ¹Î ¾à±¹ ÆÄÆ® ¾à»ç ä¿ë ¹Ù·Î°¡±â ¼¿Æ®¸®¿Â 2025³â 1Â÷ ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë ¹Ù·Î°¡±â 0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2025,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : º¹ÁöºÎ Æó¾Ï¾à ·ÎºñÅ¥¾Æ, ÃÖ´ëÇÑ »¡¸® ±Þ¿© È®´ë URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö
ä¿ëÁ¤º¸ º¹ÁöºÎ "Æó¾Ï¾à ·ÎºñÅ¥¾Æ, ÃÖ´ëÇÑ »¡¸® ±Þ¿© È®´ë" ±â»çÀÔ·Â : 24.10.16 17:12:03 0 °¡ ÇÃÄ£Ãß°¡ ÇöÀç Á¦¾à»ç¿Í Çù»ó Áß¡¦È¯ÀÚ ºÎ´ã ´úµµ·Ï ³ë·Â [µ¥Àϸ®ÆÊ=ÀÌŹ¼ø ±âÀÚ] º¹ÁöºÎ°¡ ALK ¾ç¼º ºñ¼Ò¼¼Æ÷Æó¾ÏÄ¡·áÁ¦ '·ÎºñÅ¥¾Æ(·Ñ¶óƼ´Õ)'ÀÇ 1Â÷ Ä¡·á ±Þ¿© È®´ë¿¡ ´ëÇØ ÃÖ´ëÇÑ »¡¸® ³ë·ÂÇÏ°Ú´Ù°í ¹àÇû´Ù. 16ÀÏ ¿¸° ±¹È¸ º¸°Çº¹ÁöÀ§¿øȸ ±¹Á¤°¨»ç¿¡¼ ÇÑÁö¾Æ ±¹¹ÎÀÇÈû ÀÇ¿øÀº ÇÑ ³²¼ºÀÇ »ç¿¬À» ¼Ò°³ÇÏ¸é¼ ·ÎºñÅ¥¾ÆÀÇ ±Þ¿©È®´ë ³»¿ëÀ» ¹°¾ú´Ù. ÇÑ ÀÇ¿ø¿¡ µû¸£¸é ÀÌ ³²¼ºÀº ALK ¾ç¼º ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ °É¸° ¾Æ³»¸¦ »ì¸®±â À§ÇØ ºñ±Þ¿©·Î ·ÎºñÅ¥¾Æ¸¦ ÇÑ´Þ 500¸¸¿ø µé¾î »ç¿ëÇÏ°í ÀÖ´Ù. ÇÏÁö¸¸ Á¡Á¡ ¾à°ªÀÌ ºÎ´ãÀÌ µÇ´Â »óȲ. ·ÎºñÅ¥¾Æ´Â ±Þ¿© ÀûÁ¤¼º ½É»ç¸¦ ³¡³»°í ¾à°¡Çù»ó±îÁö °¬Áö¸¸, ÇÕÀÇ°¡ ºÒ¹ßµÈ »óȲÀÌ´Ù. ÇÑ ÀÇ¿ø ÁúÀÇ¿¡ ÀÌÁß±Ô º¹ÁöºÎ °Ç°º¸ÇèÁ¤Ã¥±¹ÀåÀº "·ÎºñÅ¥¾Æ´Â ÇöÀç 1Â÷ Ä¡·á È®´ë ÀÛ¾÷À» ÇÏ°í ÀÖ´Ù"¸ç "Á¦¾à»ç¿Í Çù»óÇÏ°í ÀÖ´Ù"°í ¸»Çß´Ù. ±×·¯¸é¼ "ÃÖ´ëÇÑ »¡¸® Çù»óÇؼ ȯÀڵ鿡°Ô ÇýÅÃÀÌ µ¹¾Æ°¥ ¼ö ÀÖµµ·Ï µ½°Ú´Ù"°í µ¡ºÙ¿´´Ù. X AD ¼º£ÀÌ Âü¿© GO À̺¥Æ®Âü¿© ¡æ ÀÌŹ¼ø ±âÀÚ(hooggasi2@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç (Sr.) Local Research Specialist ¹Ù·Î°¡±â ÀÓ»óÆÀ PM °æ·Â(2³â ÀÌ»ó) ä¿ë ¹Ù·Î°¡±â ÀÓ»óÆÀ¿ø(Á¤±ÔÁ÷), RA/QAÆÀ¿ø,PVÆÀ¿ø(°è¾àÁ÷) ä¿ë ¹Ù·Î°¡±â Ç°Áú±×·ìÀå(ÀÌ»ç±Þ), °ü¸®¾à»ç ¸ðÁý ¹Ù·Î°¡±â [À¯¸í¿Ü±¹°èÁ¦¾à»ç] ½ÅÀÔ¾à»ç & °æ·Â MSL µî ´Ù¼ö ¹Ù·Î°¡±â Senior Regulatory Science Specialist(1Yr) ¹Ù·Î°¡±â Á¶¾ÆÁ¦¾à Ç°Áú°ü¸®¾à»ç °æ·Â ä¿ë ¹Ù·Î°¡±â °³¹ß±âȹÆÀ BD °æ·Â(7³â ÀÌ»ó)ä¿ë ¹Ù·Î°¡±â ¢ß¼¿Æ®¸®¿ÂÁ¦¾à ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë ¹Ù·Î°¡±â Æĸ¶¿¡¼¾½Ã¾ÆÄÚ¸®¾Æ MSL ½Å±Ô ä¿ë ¹Ù·Î°¡±â ÇØÅÂhtb ÀÍ»ê°øÀå °ü¸®¾à»ç ä¿ë ¹Ù·Î°¡±â (ÀüºÏ(ÀüÁÖ °ÅÁÖ)) ¿µ¾÷ºÎ ½ÅÀÔ/°æ·ÂÁ÷(ÁÖÀÓ~´ë¸®±Þ) ¸ðÁý ¹Ù·Î°¡±â Medical Representative (Á¾º´ ¿µ¾÷ - °è¾àÁ÷) ¹Ù·Î°¡±â Junior Marketing Manager ä¿ë ¹Ù·Î°¡±â PMS Lead (Fixed-term) ¹Ù·Î°¡±â Medical Science Liaison (Oncology) / Head of Market Access & External Affairs / MR(¿µ¾÷ºÎ) ä¿ë ¹Ù·Î°¡±â Çѱ¹¿¡ÀÚÀÌ Medical Scientific Affair ä¿ë(À°¾ÆÈÞÁ÷´ëü_±â°£Á¦) ¹Ù·Î°¡±â Medical Representative (Ŭ¸®´Ð ¿µ¾÷ - °è¾àÁ÷) ¹Ù·Î°¡±â Çѱ¹¿¡ÀÚÀÌ Sr. MSL Associate ä¿ë(Á¤±ÔÁ÷) ¹Ù·Î°¡±â Á¦¾à¾à»çä¿ë ¹Ù·Î°¡±â ¸¶ÄÉÆà ¾à»ç, Àü¹®¿¬±¸¿ä¿ø ¸ðÁý ¹Ù·Î°¡±â QC, QA, Medical Affairs, MR(º´¿ø¿µ¾÷) ä¿ë ¹Ù·Î°¡±â Sr. Regulatory Affairs Specialist (18 months contract) ¹Ù·Î°¡±â ´õÇö´ë ¼¿ï ÇÍŸ¹Î ¾à±¹ ÆÄÆ® ¾à»ç ä¿ë ¹Ù·Î°¡±â ¼¿Æ®¸®¿Â 2025³â 1Â÷ ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë ¹Ù·Î°¡±â 0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2025,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : º¹ÁöºÎ Æó¾Ï¾à ·ÎºñÅ¥¾Æ, ÃÖ´ëÇÑ »¡¸® ±Þ¿© È®´ë URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö
ä¿ëÁ¤º¸ º¹ÁöºÎ "Æó¾Ï¾à ·ÎºñÅ¥¾Æ, ÃÖ´ëÇÑ »¡¸® ±Þ¿© È®´ë" ±â»çÀÔ·Â : 24.10.16 17:12:03 0 °¡ ÇÃÄ£Ãß°¡ ÇöÀç Á¦¾à»ç¿Í Çù»ó Áß¡¦È¯ÀÚ ºÎ´ã ´úµµ·Ï ³ë·Â [µ¥Àϸ®ÆÊ=ÀÌŹ¼ø ±âÀÚ] º¹ÁöºÎ°¡ ALK ¾ç¼º ºñ¼Ò¼¼Æ÷Æó¾ÏÄ¡·áÁ¦ '·ÎºñÅ¥¾Æ(·Ñ¶óƼ´Õ)'ÀÇ 1Â÷ Ä¡·á ±Þ¿© È®´ë¿¡ ´ëÇØ ÃÖ´ëÇÑ »¡¸® ³ë·ÂÇÏ°Ú´Ù°í ¹àÇû´Ù. 16ÀÏ ¿¸° ±¹È¸ º¸°Çº¹ÁöÀ§¿øȸ ±¹Á¤°¨»ç¿¡¼ ÇÑÁö¾Æ ±¹¹ÎÀÇÈû ÀÇ¿øÀº ÇÑ ³²¼ºÀÇ »ç¿¬À» ¼Ò°³ÇÏ¸é¼ ·ÎºñÅ¥¾ÆÀÇ ±Þ¿©È®´ë ³»¿ëÀ» ¹°¾ú´Ù. ÇÑ ÀÇ¿ø¿¡ µû¸£¸é ÀÌ ³²¼ºÀº ALK ¾ç¼º ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ °É¸° ¾Æ³»¸¦ »ì¸®±â À§ÇØ ºñ±Þ¿©·Î ·ÎºñÅ¥¾Æ¸¦ ÇÑ´Þ 500¸¸¿ø µé¾î »ç¿ëÇÏ°í ÀÖ´Ù. ÇÏÁö¸¸ Á¡Á¡ ¾à°ªÀÌ ºÎ´ãÀÌ µÇ´Â »óȲ. ·ÎºñÅ¥¾Æ´Â ±Þ¿© ÀûÁ¤¼º ½É»ç¸¦ ³¡³»°í ¾à°¡Çù»ó±îÁö °¬Áö¸¸, ÇÕÀÇ°¡ ºÒ¹ßµÈ »óȲÀÌ´Ù. ÇÑ ÀÇ¿ø ÁúÀÇ¿¡ ÀÌÁß±Ô º¹ÁöºÎ °Ç°º¸ÇèÁ¤Ã¥±¹ÀåÀº "·ÎºñÅ¥¾Æ´Â ÇöÀç 1Â÷ Ä¡·á È®´ë ÀÛ¾÷À» ÇÏ°í ÀÖ´Ù"¸ç "Á¦¾à»ç¿Í Çù»óÇÏ°í ÀÖ´Ù"°í ¸»Çß´Ù. ±×·¯¸é¼ "ÃÖ´ëÇÑ »¡¸® Çù»óÇؼ ȯÀڵ鿡°Ô ÇýÅÃÀÌ µ¹¾Æ°¥ ¼ö ÀÖµµ·Ï µ½°Ú´Ù"°í µ¡ºÙ¿´´Ù. X AD ¼º£ÀÌ Âü¿© GO À̺¥Æ®Âü¿© ¡æ ÀÌŹ¼ø ±âÀÚ(hooggasi2@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç
0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2025,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : º¹ÁöºÎ Æó¾Ï¾à ·ÎºñÅ¥¾Æ, ÃÖ´ëÇÑ »¡¸® ±Þ¿© È®´ë URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö